The changing IPL landscape: How advances in light-based technology are reshaping the treatment of MGD

Intense pulsed light (IPL) therapy is changing the way eye care providers manage patients with dry eye disease associated with meibomian gland dysfunction (MGD). What began as an observation in patients being treated for facial rosacea has evolved into a meaningful therapeutic approach supported by a growing body of clinical evidence.^1-9

The evolution of IPL is not limited to its expanding role in ocular surface disease. The technology itself continues to evolve. Advances in handpiece design, energy delivery, pulse structure, and treatment ergonomics are creating new opportunities to refine how light-based therapy is delivered around the delicate periocular region. Understanding these developments begins with understanding the interaction between electromagnetic radiation and human tissue.

Harnessing the power of light

IPL uses broad-spectrum, noncoherent, polychromatic light delivered in short pulses. Unlike a laser, which typically delivers a specific wavelength, IPL systems use filters and treatment parameters to select a range of wavelengths for a desired tissue effect.^4,5,11 Wavelength influences both the chromophore being targeted and the depth of tissue penetration. In general, shorter wavelengths are absorbed more superficially whereas longer wavelengths penetrate more deeply into tissue. By selecting appropriate wavelengths and treatment parameters, IPL can deliver energy to specific biological targets while limiting unnecessary exposure to surrounding tissues. Although wavelength selection is critical, it represents only one component of treatment performance. Clinical outcomes are also influenced by fluence, pulse duration, pulse structure, spot geometry, treatment overlap, and tissue characteristics. Together, these variables determine how efficiently light energy is transferred to the intended chromophore while minimizing unnecessary heating of surrounding tissue.^4,11

For patients with MGD and ocular rosacea, one of the most important targets is hemoglobin within abnormal superficial blood vessels. Hemoglobin acts as a chromophore, absorbing selected wavelengths of light and converting that energy into heat. This process can produce photocoagulation of abnormal telangiectatic vessels.^4,5 Telangiectatic vessels are frequently associated with chronic inflammation. In patients with rosacea, abnormal vessels may be visible across the cheeks and nose, but the inflammatory process often extends to the eyelids and lid margins.^4-6 The vascular and inflammatory environments of the face and periocular tissues are interconnected. This results in the ocular and facial manifestations of rosacea frequently coexisting.^4,5

The rosacea-MGD connection

The patient with facial rosacea provides the clearest example of why IPL has become relevant to eye care. Although rosacea is a complex inflammatory disorder, patients frequently demonstrate facial erythema and telangiectatic vessels. Similar vascular and inflammatory findings are often also present along the eyelid margins.^4-6

Clinically, these patients may demonstrate lid margin hyperemia and telangiectasia as well as obstruction and capping of the meibomian gland orifices with altered meibum quality and expressibility. This can lead to reduced tear film stability, corneal and conjunctival staining, lid wiper epitheliopathy, anterior displacement of the Marx line, and ocular burning, irritation, fluctuating vision, and discomfort.^1,4-6

Chronic inflammation and obstruction can compromise the structure and function of the meibomian gland. As gland health and function decrease, the quality of the lipid layer of the tear film reduces and evaporation increases, ultimately reducing tear film stability.^1,4,5

More than 1 mechanism

A frequently proposed mechanism of IPL is selective photothermolysis of abnormal superficial vessels. When hemoglobin absorbs the delivered light energy, heat is generated within the vessel, producing coagulation, reducing the prominence of telangiectatic vessels, and reducing inflammatory mediators in the skin of the periorbital region.^4,5

Vascular photocoagulation is only part of the story. Proposed mechanisms of IPL in MGD also include reduction of proinflammatory mediators, thermal effects that may improve meibum fluidity and expression, modulation of abnormal inflammatory signaling, and improvements in tear film stability and meibomian gland function. Although vascular photocoagulation remains the most recognized mechanism, successful treatment of MGD likely reflects the cumulative effects of multiple biological processes occurring simultaneously. IPL may influence inflammatory cytokines, improve meibum quality and expressibility, reduce bacterial and Demodex populations, improve gland function, and enhance tear film stability. Appreciating these multiple mechanisms helps explain why treatment outcomes often extend beyond simple reduction of telangiectatic vessels.^4-6,10

Traditional IPL, from dermatology platforms to purpose-built ocular systems

Traditional IPL systems were largely developed from dermatologic and aesthetic platforms. Many incorporated contact cooling within the treatment handpiece to protect the epidermis and improve patient comfort during energy delivery.¹¹ IPL delivers high-intensity pulses that some patients describe as a snapping sensation against the skin. Contact cooling can improve comfort and help manage epidermal heat.¹¹

However, technologies originally designed for larger areas of the face and body are not always ideally suited to the small contours of the periocular region. Larger handpieces, fluid-circulation systems, and heavier hoses can create ergonomic challenges when treating around the nose, cheeks, and eyelids. These systems were originally engineered for larger treatment areas commonly encountered in dermatology. As IPL has become increasingly used around the eyelids and periocular tissues, the unique anatomical requirements of eye care have driven interest in platforms designed specifically for smaller treatment fields and greater operator precision.

The emergence of noncooled handpieces

Contemporary IPL platforms have introduced handpieces that do not rely on circulating water for contact cooling. From an ergonomic perspective, this represents a meaningful change. Eliminating circulating water from the treatment handpiece reduces both applicator weight and hose bulk, allowing improved maneuverability around the nose, eyelids, and facial contours. A lighter handpiece may reduce operator fatigue during repetitive treatments while improving precision and consistency of pulse placement in anatomically challenging areas.

This may be particularly relevant in eye care, where treatment precision and operator control are critical. Improved ergonomics may also reduce unintended variations in handpiece angle, treatment overlap, and applied pressure, factors that can influence treatment consistency even though they are rarely discussed in clinical studies.

IPL depends on the interaction between light energy and target chromophores.^4,5,11 It is reasonable to ask whether cooling the treatment surface alters the thermal environment in which energy is delivered. Cooling the region constricts the blood vessels, which theoretically makes the chromophores that are being targeted more difficult to obtain via the light energy. Findings from direct comparative studies demonstrating superior ocular surface outcomes with noncooled vs cooled IPL handpieces are currently unavailable.

Refining pulse delivery

Pulse structure represents another area of technological evolution. The biological effect of IPL is influenced by multiple variables, including wavelength spectrum, fluence, pulse duration, tissue characteristics, target chromophore, and skin pigmentation.^4,5,11

Modern systems increasingly allow greater control over how energy is distributed during treatment. Rather than viewing an IPL pulse simply as an on-or-off event, clinicians can consider how a given amount of energy is delivered over time.

Pulse duration should also be considered relative to the thermal relaxation time of the target tissue. Delivering energy over a period shorter than the thermal relaxation time theoretically confines heat within the target chromophore before significant diffusion into surrounding tissues can occur. This principle forms one of the foundations of selective photothermolysis. Pulse duration can also influence how selectively energy is transferred to a vascular target relative to surrounding tissue.¹¹ These concepts are well established in the broader field of selective photothermolysis.¹¹

As IPL technology matures, engineering considerations may become increasingly important. Handpiece weight, hose flexibility, pulse architecture, treatment ergonomics, cooling strategy, and applicator geometry all influence how consistently energy can be delivered to delicate periocular tissues. These factors receive considerably less attention than wavelength or fluence but may ultimately contribute to treatment reproducibility and operator experience. As IPL platforms continue to evolve, future clinical trials should evaluate not simply whether IPL works but which combinations of wavelength, fluence, pulse structure, treatment interval, and adjunctive therapy provide the best outcomes for specific patient phenotypes.

Engineering beyond fluence

Historically, IPL platforms have often been compared primarily by fluence or wavelength selection. Although these variables remain important, they represent only part of the treatment equation. Treatment performance is also influenced by pulse duration, pulse architecture, applicator design, ergonomics, cooling strategy, treatment overlap, and operator precision.

Unlike larger facial aesthetic treatments, periocular IPL frequently requires precise energy placement along curved facial contours while maintaining consistent overlap between adjacent pulses. Applicator design, hose flexibility, and overall handpiece weight may therefore influence treatment reproducibility more than is commonly appreciated.

Advances in pulse architecture may represent one of the most significant developments in modern IPL design. Delivering energy over extremely short pulse durations increases instantaneous power while limiting thermal diffusion into adjacent tissue. This may improve selective energy confinement within target chromophores while minimizing unnecessary collateral heating.

Conclusion

The power of light energy is clearly changing the management of ocular surface disease associated with MGD.^1-9 IPL has moved from an unexpected observation in patients treated for facial rosacea to an increasingly evidence-supported therapy for MGD-related dry eye disease. Its effects appear to extend beyond a single mechanism, potentially influencing abnormal vasculature, inflammation, meibum characteristics, and tear film stability.^2-10

References

1. Jones L, Craig JP, Markoulli M, et al; TFOS Collaborator Group. TFOS DEWS III: management and therapy. Am J Ophthalmol. 2025;279:289-386. doi:10.1016/j.ajo.2025.05.039

2. Toyos R, Desai NR, Toyos M, Dell SJ. Intense pulsed light improves signs and symptoms of dry eye disease due to meibomian gland dysfunction: a randomized controlled study. PLoS One. 2022;17(6):e0270268. doi:10.1371/journal.pone.0270268

3. Xue AL, Wang MTM, Ormonde SE, Craig JP. Randomized double-masked placebo-controlled trial of the cumulative treatment efficacy profile of intense pulsed light therapy for meibomian gland dysfunction. Ocul Surf. 2020;18(2):286-297. doi:10.1016/j.jtos.2020.01.003

4. Giannaccare G, Taroni L, Senni C, Scorcia V. Intense pulsed light therapy in the treatment of meibomian gland dysfunction: current perspectives. Clin Optom (Auckl). 2019;11:113-126. doi:10.2147/OPTO.S217639

5. Suwal A, Hao JL, Zhou DD, Liu XF, Suwal R, Lu CW. Use of intense pulsed light to mitigate meibomian gland dysfunction for dry eye disease. Int J Med Sci. 2020;17(10):1385-1392. doi:10.7150/ijms.44288

6. Ribeiro BB, Marta A, Ramalhão JP, Marques JH, Barbosa I. Pulsed light therapy in the management of dry eye disease: Current perspectives. Clin Ophthalmol. 2022;16:3883-3893. doi:10.2147/OPTH.S349596

7. D'Souza S, James E, Koul A, Modak D, Kundu G, Shetty R. A randomized controlled study evaluating outcomes of intense pulsed light and low-level light therapy for treating meibomian gland dysfunction and evaporative dry eye. Indian J Ophthalmol. 2023;71(4):1608-1612. doi:10.4103/IJO.IJO_2834_22

8. Wladis EJ, Aakalu VK, Foster JA, et al. Intense pulsed light for meibomian gland disease: a report by the American Academy of Ophthalmology. Ophthalmology. 2020;127(9):1227-1233. doi:10.1016/j.ophtha.2020.03.009

9. Arita R, Fukuoka S, Morishige N. Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocul Surf. 2019;17(1):104-110. doi:10.1016/j.jtos.2018.11.004

10. Choi M, Han SJ, Ji YW, et al. Meibum expressibility improvement as a therapeutic target of intense pulsed light treatment in meibomian gland dysfunction and its association with tear inflammatory cytokines. Sci Rep. 2019;9(1):7648. doi:10.1038/s41598-019-44000-0

11. Goldberg DJ. Current trends in intense pulsed light. J Clin Aesthet Dermatol. 2012;5(6):45-53.